한글목차

세계의 비강 백신 시장은 2025년 4억 9,180만 달러로 추정되고, 2032년까지 8억 7,620만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 CAGR 8.6%로 성장할 전망입니다.

비강 백신은 코에서 투여되는 백신으로 주사하지 않고 면역 반응을 자극합니다. 바이러스가 최초로 체내에 침입하는 코로부터 투여되기 때문에 감염의 사이클을 멈추고, 감염을 저지하고, 다른 부작용을 포함한 폐 장애를 저지하는 능력이 있다고 홍보되고 있습니다. 그 때문에 시장 관계자는 안전하고 효과적인 경비 백신의 개발에 주력하고 있습니다.

시장 역학:

호흡기 질환과 감염증의 부담 증가, COVID-19의 발생, 안전하고 효과적인 백신 개발에 대한 주목의 높아짐, 안전하고 효과적인 백신에 대한 수요 증가, 연구개발 활동의 활성화 등이 예측 기간 중의 비강용 백신 세계 시장의 성장을 가속할 것으로 예상되는 주요 요인입니다.

예를 들어 2023년 1월 인도에 본사를 둔 세계 바이오의약품 기업인 Bharat Biotech는 인도 최초의 비강내 COVID-19 백신인 iNCOVACC를 1차 투여뿐만 아니라 이종 혼합(믹스 앤 매치) 부스터 투여용으로 인도에서 발매한다고 발표했습니다. 이종 부스터 용량으로서 인도 의약품 관리 총국(DCGI)에 의해 승인되고 있습니다.

본 조사의 주요 특징

• 본 보고서에서는 세계의 경비 백신 시장을 상세하게 분석했으며, 2024년을 기준연도로 한 예측 기간(2025-2032년) 시장 규모 및 CAGR을 제공합니다.
• 또, 다른 부문에 걸친 잠재적인 수익 성장 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스를 해설했습니다.
• 또 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 주요 고찰도 제공합니다.
• 아래의 파라미터, 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략에 따라 비강용 백신 세계 시장에서 주요 기업을 프로파일하고 있습니다.
• 이 조사의 대상이되는 주요 기업은 AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., SINOVAC, Bharat Biotech, Altimmune, FluGen Inc., Vaxart, Intravacc, Gamma Vaccines Pty Ltd., BioNTech SE 등을 포함합니다.
• 본 보고서로부터의 통찰에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 발매, 유형, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
• 비강용 백신 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 하고 있습니다.
• 이해관계자는 세계의 비강 백신 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 제품 출시/승인
• PEST 분석
• PORTER 분석
• 합병과 인수 시나리오

제4장 세계의 비강 백신 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측의 분석
• 경제에 미치는 영향

제5장 세계의 비강 백신 시장 : 백신 유형별, 2020-2032년

• 생약독화 백신
• 불활성화 백신
• 아단위 백신, 재조합 백신, 결합 백신
• 기타(DNA 백신, 바이러스 벡터 백신 등)

제6장 세계의 비강 백신 시장 : 용도별, 2020-2028년

• 인플루엔자
• COVID-19
• 기타 호흡기 감염증(RS 바이러스 감염증, 폐렴구균 감염증 등)
• 기타(콜레라, 장티푸스 등)

제7장 세계의 비강 백신 시장 : 유통 채널별, 2025-2028년

• 공공
• 민간

제8장 세계의 비강 백신 시장 : 지역별, 2020-2032년

• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 이탈리아
  • 프랑스
  • 스페인
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • ASEAN
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
• 중동
  • GCC
  • 이스라엘
  • 기타 중동
• 아프리카
  • 북아프리카
  • 중앙 아프리카
  • 남아프리카

제9장 경쟁 구도

• AstraZeneca
• GlaxoSmithKline plc
• Pfizer Inc.
• Serum Institute of India Pvt. Ltd.
• SINOVAC
• Bharat Biotech
• Altimmune
• FluGen Inc.
• Vaxart
• Intravacc
• Gamma Vaccines Pty Ltd.
• BioNTech SE

제10장 섹션

• 조사 방법
• 출판사에 대해

영문목차

Nasal Vaccines Market is estimated to be valued at USD 491.8 Mn in 2025 and is expected to reach USD 876.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.

Nasal vaccine is a vaccine administered through the nose that stimulates an immune response without an injection. A vaccine dose is given via nose, rather than orally or through the arm. While several versions of a nasal vaccine are in development, most are in preclinical stages. A nasal vaccine is touted to have the ability to end the cycle of transmission, stop infection, and stop lung damage, including other adverse effects as the dose is administered through the nose, where the virus first enters the body. Thus, market players are focusing on developing safe/effective nasal vaccines.

Market Dynamics:

The rising burden of respiratory diseases or infections, outbreak of COVID-19, increasing focus on the development of safe and effective vaccines, increasing demand for safe and effective vaccines, and increasing research and development activities are the major factors expected to propel the growth of the global nasal vaccines market over the forecast period.

For instance, in January 2023, Bharat Biotech, an Indian-based global biopharmaceutical company announced the launch of India's first intra-nasal COVID-19 vaccine, iNCOVACC for a primary as well as heterologous (mix-and-match) booster dose in India. It was the first nasal COVID-19 vaccine that was approved both as a primary two-dose regimen, and a heterologous booster after two doses of Covishield or Covaxin. It is approved by the Drugs Control General of India (DCGI) as a heterologous booster dose. The new iNCOVACC vaccine can potentially revolutionize the battle against COVID-19 infection.

Key Features of the Study:

• This report provides an in-depth analysis of the global nasal vaccines market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global nasal vaccines market based on the following parameters, company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., SINOVAC, Bharat Biotech, Altimmune, FluGen Inc., Vaxart, Intravacc, Gamma Vaccines Pty Ltd., and BioNTech SE
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global nasal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal vaccines market

Detailed Segmentation:

• By Vaccine Type:
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit, Recombinant, and Conjugate Vaccines
  • Others (such as DNA Vaccines, Viral Vector Vaccines, etc.)
• By Application:
  • Influenza
  • COVID-19
  • Other Respiratory Infections (such as RSV, Pneumococcal, etc.)
  • Others (such as Cholera, Typhoid, etc.)
• By Distribution Channel:
  • Public
  • Private
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca,
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • SINOVAC
  • Bharat Biotech
  • Altimmune
  • FluGen Inc.
  • Vaxart
  • Intravacc
  • Gamma Vaccines Pty Ltd.
  • BioNTech SE

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Nasal Vaccines Market, By Vaccine Type
  • Global Nasal Vaccines Market, By Application
  • Global Nasal Vaccines Market, By Distribution Channel
  • Global Nasal Vaccines Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rising burden of respiratory diseases or infections
  • Lack of healthcare infrastructure in developing economies
  • Increasing demand for safe and effective vaccines
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Nasal Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Nasal Vaccines Market, By Vaccine Type, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Live Attenuated Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Inactivated Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Subunit, Recombinant, and Conjugate Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Others (such as DNA Vaccines, Viral Vector Vaccines, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global Nasal Vaccines Market, By Application, 2020-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Influenza
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• COVID-19
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Other Respiratory Infections (such as RSV, Pneumococcal, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Others (such as Cholera, Typhoid, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Nasal Vaccines Market, By Distribution Channel, 2025-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global Nasal Vaccines Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Serum Institute of India Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• SINOVAC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bharat Biotech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Altimmune
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• FluGen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Vaxart
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Intravacc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gamma Vaccines Pty Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BioNTech SE
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us